COMMUNIQUÉS West-GlobeNewswire

-
electroCore Appoints Medical Technology Veteran Daniel S. Goldberger as Chief Executive Officer
30/09/2019 -
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma
30/09/2019 -
TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer
30/09/2019 -
ORYZON Presents Positive Efficacy Results on Iadademstat in ED-SCLC Patients at ESMO-2019
30/09/2019 -
Further Data Review Shows Major Clinical Benefits From Veyonda®
30/09/2019 -
Kaleido Biosciences Announces Appointment of Jean Mixer to its Board of Directors
30/09/2019 -
Intra-Cellular Therapies to Present at the 2019 Cantor Global Healthcare Conference
30/09/2019 -
CymaBay Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
30/09/2019 -
Krystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference
30/09/2019 -
BioSig to Present Clinical Observations at Venice Arrhythmias 2019
30/09/2019 -
Acarix publish EU growth prospectus in connection with rights issue of up to approximately SEK 51.8 million
30/09/2019 -
T2 Biosystems’ T2Resistance™ Panel is Now Available as a Research Use Only (RUO) Test in the U.S.
30/09/2019 -
Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors
30/09/2019 -
Translate Bio to Present at the 3rd Annual Chardan Genetic Medicines Conference
30/09/2019 -
Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019
30/09/2019 -
Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
30/09/2019 -
Syneos Health Introduces New Book, Why We Resist: The Surprising Truths About Motivating Behavior Change
30/09/2019 -
TG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib (“U2”) in Blood
30/09/2019 -
CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term
30/09/2019
Pages